Chang David D 4
4 · Allogene Therapeutics, Inc. · Filed Mar 25, 2022
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2022-03-23+2,195,512→ 2,195,512 totalExercise: $9.69Exp: 2032-03-23→ Common Stock (2,195,512 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter